As part of our series focussing on available medicines in Australia, we have added a product review of use of high-dose quadrivalent influenza vaccine as protection for high-risk patients.
This review discusses vulnerability of older patients, pharmacological properties, drug interactions and major studies focussed on vaccine use for high-risk patients. It also provides commentary and recommendations from Associate Professor John Amerena, a Cardiologist at Barwon Health and Director of the Geelong Cardiology Research Unit.
Please login below to download this issue (PDF)